Second Annual CDD Community Meeting

October 7, 2008

2rd community meeting logoThe 2nd CDD Community Meeting was wildly successful with 176 registrants and 20 Posters.

The symposium speakers presented on important research and collaboration around neglected diseases and orphan drugs. The Keynote presentation by J. Leighton Read of Alloy Ventures provided crucial insight into how pre-clinical research affects clinical drug development. The Discussion Panels featured members of the QB3 Screening Centers highlighting successful collaboration, and representatives of five collaborative foundations assessing key issues in academic partnerships.

Presentation Slides (PDF) & Audio Recordings (MP3)

  • Welcome & Introduction
    Barry Bunin, PhD
    Collaborative Drug Discovery
    Biography | Audio | Slides
  • Repurposing approved clinical drugs for protozoan diseases
    David Sullivan, MD
    Johns Hopkins University Bloomberg School Public Health
    Abstract & Bio | Audio | Slides
  • Data Management in an Academic Drug Discovery Program
    Fred Buckner, MD
    University of Washington, Department of Medicine
    Abstract & Bio | Audio | Slides
  • A ‘Broad’ View of Translational Research at the Stanley Center
    Janice E. Kranz, PhD
    The Broad Institute of MIT and Harvard
    Abstract & Bio | Audio | Slides
  • Novel drugs for schistosomiasis: establishment of a medium-throughput whole-organism screen at UCSF
    Conor Caffrey, PhD
    Sandler Center for Basic Research – University of California, San Francisco
    Abstract & Bio | Audio | Slides
  • Computational Drug Discovery: Integrating A Collaborative Database
    Sean Ekins, PhD
    Collaborations in Chemistry & UMDN
    Abstract & Bio | Audio | Slides
  • High Quality Compound Libraries Inspired by Nature
    Andrea Altieri, PhD, ASINEX Corporation
    Abstract & Bio | Audio | Contact Author Regarding Slides
  • High Throughput Screening as a Research Tool
    Robert Damoiseaux, PhD
    UCLA Molecular Screening Shared Resource Center
    Abstract & Bio| Audio| Slides
  • Using Chemical Genomics to explore the HER-kinase axis in Prostate Cancer
    Anjali Jain, PhD
    Cedars-Sinai Medical Center & UCLA
    Biography| Audio| Slides
  • High throughput screen to discover inhibitors of brain cancer stem cells
    Koppany Visnyei, MD, PhD
    Crump Institute for Molecular Imaging, UCLA
    Biography| Audio| Slides
  • CDD Community Software Vision and Roadmap
    Moses Hohman, PhD
    Collaborative Drug Discovery, Inc.
    Abstract & Bio | Audio| Slides
  • What are foundations looking for from academic researchers?
    Victoria Hale, PhD, Founder
    One World Health
    Biography | Audio | No Slides Displayed
  • What are foundations looking for from academic researchers?
    Catherine Ley, PhD, Director of Virtual Biotech Collaborations
    Biography | Audio | Slides
  • Keynote #1: Financing Biomedical Innovation from academia to the market: From FluMIst™ to Priority Review Vouchers and other stories
    J. Leighton Read, MD, Alloy Ventures
    Abstract & Bio | Audio | Slides
  • Keynote #2: How CDD is helping the MRF Accelerate Validation and Drug Discovery for Novel Targets in the CNS
    Russell “Rusty” Bromley, COO, Myelin Repair Foundation
    Abstract & Bio | Presentation Held for Time | Slides
  • Panel #1: What makes collaborations successful within and between groups?
    Robert Damoiseaux, PhD, UCLA Molecular Screening Shared Resource Center
    Nadine Gassner, PhD, UCSC Chemical Screening Center
    Adam Renslo, PhD, UCSF Small Molecule Discovery Center
    Summary: Directors of the screening centers from three University of California campuses joined to discuss collaborations between internal and external research organizations, and to speculate on the future of collaborative data acquisition and management, via both technology and partnerships. Challenges of integrating data and research groups as well as collaborative successes were discussed. The audience posed questions to the panel regarding compound sources for screening, data management of High-Throughput Screening (HTS) projects, and cost. All three screening centers are putting HTS data into the CDD system.
  • Panel #2: What Foundations are looking for from Academic researchers?
    Russell Bromley – COO, Myelin Repair Foundation
    Victoria Hale – Founder, One World Health
    Catherine Ley – Director, Collabrx, Inc.
    Leighton Read – General Partner, Alloy Ventures
    Wells Whitney – Board Member, The Lung Cancer Foundation
    Summary: Key players from five research foundations reviewed the strengths and weaknesses of academic and corporate research organizations and how foundations can help select, coordinate, manage and fund academic research groups to achieve chartered discovery goals around orphaned and neglected diseases. These foundations facilitate collaborations, not just between research organizations, but also community centers and clinical centers. Considering themselves in infancy or adolescents, they have ambitious goals to organize and fund large numbers of researchers, clinicians, and even patients, to accelerate discovery of treatments and cures. Foundations hope to accomplish this by bringing organizational and functional principals of venture firms to pre-clinical and clinical processes. Accessing government programs like Priority Review Vouchers (PRV’s) and Advanced Market Commitments (AMC’s), and outsourcing drug development are just a couple of the administrative functions that foundations bring to academic collaborations.

We sincerely thank all our speakers and panel members.

The Community Meeting Program is now available online with biographies, presentation abstracts, and presented poster abstracts.

We would also like to acknowledge our sponsors without which this meeting would not have been possible.

Assay Depot logo

Assay Depot is the world’s first full service outsourcing marketplace for drug discovery research services, located online at

At, industrial and academic scientists can order a research service as easily as they can order a book at Through, scientists can synthesize drug-like compounds, clone DNA, create miniaturized protein arrays or carry out hundreds of the most critical biological, chemical and pharmacological assays done in a typical 5 to 7 year drug discovery campaign. Assay Depot’s innovative marketplace enables academic scientists to access drug discovery services that until recently were only available within industry laboratories.

Asinex logo

ASINEX is a solution provider that offers unrivalled chemistry resources, many years of experience in providing discovery chemistry services and an ever expanding range of ADMET screening options. ASINEX’s strength lies in the chemistry of small molecules, strongly supported by computational chemistry and biology. With main chemistry expertise in lead optimization, ASINEX transfers the knowledge concerning optimization factors into the design of new libraries and synthesis of compounds that are suitable for further elaboration at different levels. The Bioscreening Department provides feedback concerning what constitutes desirable and undesirable properties (solubility, permeability, toxicity, metabolism etc) for small molecule compounds, knowledge that is useful for the next generation of libraries.

CollabRx logo

CollabRx builds and operates Virtual Biotechs for foundations and patients who urgently seek cures for their diseases. Working with these foundations and research institutions, CollabRx builds teams of top researchers, facilitates planning of a strategic road map, brings best practices to therapy development, and manages the execution of the plan. The CollabRx research platform connects researchers to one another and to a network of scientific services, providing unprecedented opportunities for knowledge sharing and economies of scale.

CDD logo

Collaborative Drug Discovery (CDD) enables scientists to develop new drug candidates for commercial and humanitarian markets more effectively. CDD provides customizable, web-based research informatics tools enabling our Community to archive, mine, and collaborate around pre-clinical drug discovery chemical and biological information. Our affordable solution consolidates disparate chemical and biological data into a single repository suitable for public collaborations and secure, private research, plus CDD requires no installation or support of your computers and databases.

California Institute for Quantitative Biomedical Research (QB3) logo

The California Institute for Quantitative Biomedical Research (QB3), a cooperative effort among three campuses of the University of California and private industry, harnesses the application of the quantitative sciences – mathematics, physics, chemistry and engineering – to biomedical research.  This long-sought integration allows scientists to attack problems that have been unapproachable before; thus setting the stage for fundamental new discoveries, new products and new technologies for the benefit of human health. Furthermore, QB3 has been tasked by the State to ensure that its innovations reach patients and the marketplace as quickly as possible.  Consequently, QB3 is dedicated to promoting translational research, establishing effective partnerships with industry, and helping its faculty explore commercial opportunities for their discoveries.  QB3 also provides state-of-the-art core research facilities to its investigators and the local biotech community, including the Small Molecule Discovery Center, the UCSF Nikon Imaging Center, and high-field human magnetic resonance imaging.

J. David Gladstone Institutes logo

The J. David Gladstone Institutes is composed of three institutes. The Gladstone Institute of Cardiovascular Disease, which opened in 1979, focuses on atherosclerosis and its complications. In 1992, the Gladstone Institute of Virology and Immunology was established to study HIV, the causative agent of AIDS. The 1993 discovery that apolipoprotein E–long studied at the Gladstone Institute of Cardiovascular Disease for its role in heart disease–plays a role in Alzheimer’s disease as well led to the establishment of the Gladstone Institute of Neurological Disease in 1998.

The three institutes are located at Gladstone’s new research facility adjacent to the Mission Bay campus of UCSF. While independent, Gladstone is formally affiliated with UCSF, and Gladstone investigators hold university appointments and participate in many university activities, including the teaching and training of graduate students.

Primary research efforts at The J. David Gladstone Institutes focus on three of the most important clinical problems of modern times: cardiovascular disease, AIDS, and neurodegenerative disorders. Cardiovascular disease, the nation’s leading killer, claims the lives of over one million Americans each year. Despite more effective treatments, AIDS remains a leading cause of death in the United States. Worldwide, more than 40 million people are living with HIV/AIDS, and more than 21 million have died as a direct result of HIV infection. Alzheimer’s disease, the most recent focus of investigation by Gladstone scientists, is the fourth leading cause of death in adults, affecting four million Americans. The realization of the impact of these diseases on world health infuses Gladstone scientists with a sense of purpose and urgency.

Although autonomous in their areas of specialization, the institutes share a common approach. Each institute is organized around research units consisting of scientists, postdoctoral researchers, research associates, and students. This structure is designed to accommodate small groups of scientists who work together closely but who also benefit from collegial interactions with other research groups. Collaborations among staff members with various areas of expertise create a stimulating environment that fortifies the scientific lifeblood of the organization.

This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities!

CDD Vault: Drug Discovery Informatics your whole project team will embrace!